Sirtaz Sibia, DO
Ophthalmology · Boynton Beach, FLNPI 1679518195
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 20.7%. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 442 payments — averaging $76.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$7K
- NEW World Medical,inc.$4K
- Surgical Specialties Corporation (US), Inc. (dba Corza Medical)$4K
- AbbVie$3K
- Katena Products, Inc. (dba Corza Medical)$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- plus $11K from 33 others
Across 84 payments — averaging $4895.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$322K
- Argenx US, Inc.$89K
What the payments were for
- Consulting fees$5,01615%
- Speaking & faculty fees$4,11612%
- Travel & lodging$4,27713%
- Food & beverage$19,85959%
- Education$2681%
- Gifts$840%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Surgical wound closure product$3,750
- Kahook Dual Blade$2,991
- Ahmed Glaucoma Valve$2,991
- Clearpath$2,517
- Streamline$2,517
- Via360$1,991
- VYVGART$1,603
- LenSx$1,587
- ACTHAR$765
- TEPEZZA$671
- DURYSTA$606
- AIR OPTIX$557
- OMNI(R) SURGICAL SYSTEM (US)$551
- Clareon$551
- Streamline Surgical System$474
- Tecnis IOL$399
- Syfovre$365
- ACTIVEFOCUS$358
- VERITAS Vision System$357
- Tecnis Simplicity$335
How this compares
$33,621 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 500 | $183,008 |
| RestasisCyclosporine | 154 | $176,913 |
| CombiganBrimonidine Tartrate/Timolol | 374 | $100,933 |
| EyleaAflibercept | 40 | $100,254 |
| RhopressaNetarsudil Mesylate | 264 | $98,262 |
| Eylea HdAflibercept | 16 | $55,386 |
| XiidraLifitegrast | 43 | $45,792 |
| RocklatanNetarsudil Mesylat/Latanoprost | 86 | $42,198 |
| Alphagan PBrimonidine Tartrate | 123 | $37,372 |
| SyfovrePegcetacoplan/Pf | 15 | $34,298 |
| Prednisolone Acetate | 885 | $29,439 |
| Brimonidine Tartrate | 523 | $27,975 |
| Latanoprost | 3,151 | $26,902 |
| VyzultaLatanoprostene Bunod | 38 | $16,451 |
| Cyclosporine | 29 | $13,636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P, Botox | $3,295 | $509,8251,169 claims |
| Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd | $23 | $155,64056 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $133 | $140,460350 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,060 | $62,24381 claims |
| Apellis Pharmaceuticals, Inc.Syfovre | $491 | $34,29815 claims |
| AlconSimbrinza | $6,955 | $9,79341 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Boynton Beach
- Barry SchechterBoynton Beach$264K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.